

Express Mail No. EV 025902743 US  
Attorney Docket: ALL.02

JCE28 U.S. PTO  
10/082130  
02/25/02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	GERBER	} EXAMINER: } ART UNIT: } CONFIRMATION NO:
SERIAL NO.:	10/	
FILED:	FEBRUARY 25, 2002	
TITLE:	METHODS AND REAGENTS FOR MRI IMAGE ENHANCEMENT	

#4  
Hoda  
9/7/02

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: February 25, 2002



Darla G. Yoerg, #48,053

Swanson & Bratschun, L.L.C.

1745 Shea Center Drive, Suite 330

Highlands Ranch, Colorado 80129

Telephone: (303) 268-0066

Facsimile: (303) 268-0065

cc: Evan King

\\SWANSONBRATS01\COMPANY\CLIENT FOLDERS\ALLOS\02\IDS.DOC

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  List of Information Cited by Applicant  Page 1 of 2	<b>ATTY. DOCKET NO.</b> ALL.02	<b>SERIAL NO.</b> 10/
	<b>APPLICANT</b> GERBER	
	<b>FILING DATE</b> FEBRUARY 25, 2002	<b>GROUP</b>

JC828 U.S. PTO  
 10/082130



U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB-CLS	FILE DATE
	AA	5,049,695	09/17/91	Abraham et al.			
	AB	5,122,539	06/16/92	Abraham et al.			
	AC	5,248,785	09/28/93	Abraham et al.			
	AD	5,290,803	03/01/94	Abraham et al.			

  

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB-CLS	TRANS. ?
/	AE	WO 97/34594	03/21/97	PCT			

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AF	Abraham et al. (1992) <i>Biochem.</i> 31:9141-9149					
	AG	Abraham et al. (1998) <i>Med. Chem. Res.</i> 8:478-486					
	AH	Burke et al. (2001) <i>Kidney Intl.</i> 60:1407-1414					
	AI	Curtis et al. (1997) <i>J. Appl. Physiol.</i> 83:1681-1689					
	AJ	Doppenberg et al. (1997) <i>Annals. of the N.Y. Acad. of Sci.</i> 825:240-257					
	AK	Doppenberg et al. (1999) <i>J. Neurotrauma</i> 16:123-133					
	AL	Eichelbronner et al. (1999) <i>Am. J. Physiol.</i> 277 ( <i>Heart Circ. Physiol.</i> 46): H290-H298					
	AM	Grocott et al. (1998) <i>Stroke</i> 29:1650-1655					
	AN	Kavanagh et al. (2001) <i>Int. J. Radiation Oncology Bio. Phys.</i> 49:1133-1139					
	AO	Khandelwal et al. (1996) <i>Rad. Oncol. Invest.</i> 4:51-59					
	AP	Khandelwal et al. (1999) <i>Brit. J. Cancer</i> 79:814-820.					
	AQ	Kilgore et al. (1999) <i>Circulation</i> 100 (Supp. II):II-351 to II-356					
	AR	Kunert et al. (1996) <i>Am. J. Physiol.</i> 271 ( <i>Heart Circ. Physiol.</i> 40): H602-H613					
	AS	Kunert et al. (1996) <i>Microvasc. Res.</i> 52:58-68 (1996)					
	AT	Oja et al. (1999) <i>Magnetic Resonance in Medicine</i> 42:617-626					
	AU	Oja et al. (1999) <i>J. of Cerebral Blood Flow and Metabolism</i> 19:1289-1295					
	AV	Mackensen et al. (2000) <i>Brain Res.</i> 853:15-21					
	AW	Pagel et al. (1998) in <i>Oxygen Transport to Tissues XX</i> 653-661 (Hudetz and Bruley, eds.) 527-531					
	AX	Pagel et al. <i>J Pharmacol. Exp. Ther.</i> 285:1-8					
	AY	Randad et al. (1991) <i>J. Med. Chem.</i> 34:752-757					
	AZ	Rockwell and Kelley (1998) <i>Rad. Oncol. Invest.</i> 6:199-208					
	AAA	Safo et al. (2001) <i>Protein Sci.</i> 10:951-957.					
	AAB	Sarraf-Yazdi et al. (1999) <i>Brain Res.</i> 826:172-180					
	AAC	Steffen, R. (1998) in <i>Oxygen Transport to Tissues XX</i> 653-661 (Hudetz and Bruley, eds.)					
	AAD	Teicher et al. (1996) <i>Drug Dev. Res.</i> 38(1):1-11					
	AAE	Teicher et al. (1998) <i>Vivo, Cancer Chemother. Pharmacol.</i> 42:24-30					

  

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and <u>not</u> considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  List of Information Cited by Applicant  Page 2 of 2	<b>ATTY. DOCKET NO.</b> ALL.02	<b>SERIAL NO.</b> 10/
	<b>APPLICANT</b> GERBER	
	<b>FILING DATE</b> FEBRUARY 25, 2002	<b>GROUP</b>

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	BA	5,432,191	07/11/95	Abraham et al.			
	BB	5,525,630	06/811/96	Hoffman			
	BC	5,648,375	07/15/97	Abraham			
	BD	5,661,182	08/26/97	Abraham et al.			
	BE	5,677,330	10/14/97	Abraham et al.			
	BF	5,705,521	01/06/98	Abraham			
	BG	5,827,888	10/27/98	Abraham et al.			
	BH	5,927,283	07/27/99	Abraham et al.			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	BI						
	BJ						
	BK						

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	BL	Van Zijl et al. (1998) <i>Nat. Med.</i> 4(2):159-167
	BM	Wahr et al. (2001) <i>Anesth. Analg.</i> 92:615-620
	BN	Watson et al. (1997) <i>Stroke</i> 28:1624-1630
	BO	Wei, et al. (1993) <i>Am. J. Physiol.</i> 265 ( <i>Heart Circ. Physiol.</i> 34) H1439-H1443
	BP	Weiss et al. (1999) <i>J. Clin. Invest.</i> 103:739-746
	BQ	Woods et al. (1998) <i>J Cardiovasc. Pharmacol.</i> 31:359-363
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

\\SWANSONBRATS01\COMPANY\Client Folders\Allos\02\IDS.doc